Clinical Trials Directory

Trials / Completed

CompletedNCT01568021

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)

Status
Completed
Phase
Study type
Observational
Enrollment
100 (actual)
Sponsor
Allergan · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.

Conditions

Interventions

TypeNameDescription
OTHERNo InterventionNo intervention was administered in this study.

Timeline

Start date
2011-10-01
Primary completion
2013-11-01
Completion
2013-11-01
First posted
2012-04-02
Last updated
2015-02-10
Results posted
2015-02-10

Locations

3 sites across 3 countries: Denmark, Norway, Sweden

Source: ClinicalTrials.gov record NCT01568021. Inclusion in this directory is not an endorsement.

Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO) (NCT01568021) · Clinical Trials Directory